AGTR1 and Parkinson disease: We have recently observed an increase in AT1-AA expression in serum and cerebrospinal fluid in PD patients and PD experimental models, and that AT1-AA can affect dopaminergic neurons and disrupt the blood-brain barrier (BBB) (9).